Genix Pharmaceuticals Corporation
GENPF
$0.0138
-$0.0262-65.50%
OTC PK
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 100.00 | 700.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 100.00 | 700.00 |
| Cost of Revenue | -- | -- | -- | 134.10K | 300.00 |
| Gross Profit | -- | -- | -- | -134.00K | 500.00 |
| SG&A Expenses | 23.60K | 21.90K | 21.30K | 44.80K | 30.00K |
| Depreciation & Amortization | 200.00 | 200.00 | 200.00 | 200.00 | 200.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.80K | 22.10K | 21.50K | 179.10K | 30.50K |
| Operating Income | -23.80K | -22.10K | -21.50K | -179.00K | -29.80K |
| Income Before Tax | -60.80K | -36.60K | -75.50K | 112.80K | -60.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.80K | -36.60K | -75.50K | 112.80K | -60.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.80K | -36.60K | -75.50K | 112.80K | -60.00K |
| EBIT | -23.80K | -22.10K | -21.50K | -179.00K | -29.80K |
| EBITDA | -23.60K | -21.90K | -21.30K | -79.00K | -29.60K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 59.22M | 59.22M | 59.22M | 59.22M | 59.22M |
| Average Diluted Shares Outstanding | 59.22M | 59.22M | 59.22M | 59.22M | 59.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |